Cubist Systematic Strategies LLC Decreases Stock Holdings in LivaNova PLC (NASDAQ:LIVN)

Cubist Systematic Strategies LLC lessened its stake in LivaNova PLC (NASDAQ:LIVN) by 55.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 38,324 shares of the company’s stock after selling 48,326 shares during the period. Cubist Systematic Strategies LLC owned 0.07% of LivaNova worth $2,101,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in LIVN. First Light Asset Management LLC grew its stake in LivaNova by 591.1% in the second quarter. First Light Asset Management LLC now owns 710,390 shares of the company’s stock valued at $38,944,000 after purchasing an additional 607,598 shares during the last quarter. Great Lakes Advisors LLC purchased a new position in LivaNova in the second quarter valued at about $16,614,000. Mesirow Institutional Investment Management Inc. purchased a new position in LivaNova in the first quarter valued at about $13,816,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in LivaNova in the fourth quarter valued at about $8,330,000. Finally, Magnetar Financial LLC grew its stake in LivaNova by 24.5% in the first quarter. Magnetar Financial LLC now owns 753,338 shares of the company’s stock valued at $42,142,000 after purchasing an additional 148,178 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Price Performance

Shares of NASDAQ LIVN opened at $52.54 on Tuesday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.94 and a current ratio of 3.45. The company has a market cap of $2.85 billion, a PE ratio of -87.57 and a beta of 1.00. The business has a 50-day simple moving average of $48.67 and a two-hundred day simple moving average of $53.35. LivaNova PLC has a fifty-two week low of $42.75 and a fifty-two week high of $64.47.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, July 31st. The company reported $0.81 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.15. LivaNova had a positive return on equity of 13.77% and a negative net margin of 1.37%. The firm had revenue of $318.60 million during the quarter, compared to the consensus estimate of $305.05 million. As a group, equities analysts expect that LivaNova PLC will post 2.58 EPS for the current fiscal year.

Wall Street Analyst Weigh In

LIVN has been the topic of several analyst reports. Stifel Nicolaus lifted their target price on LivaNova from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. Robert W. Baird raised LivaNova from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $55.00 to $66.00 in a report on Tuesday, September 17th. Finally, Needham & Company LLC raised their price target on LivaNova from $72.00 to $75.00 and gave the stock a “buy” rating in a report on Wednesday, July 31st. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $70.80.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.